Ionis’ antisense oligonucleotide olezarsen is now the first approved treatment for familial chylomicronemia syndrome, a rare metabolic disorder that prevents the body from breaking down fats called triglycerides.
Olezarsen, to be marketed as Tryngolza, is ...
↧
